Nebenwirkungen · Faslodex
Faslodex 250 mg solution for injection. · Abschnitt 4.8 · PDF-Seite 5
HOS-112836 · Präparat HOS-093769
In Table 1, the following frequency categories for adverse drug reactions (ADRs) were calculated based on the Faslodex 500 mg treatment group in pooled safety analyses of studies that compared Faslodex 500 mg with Faslodex 250 mg [CONFIRM (Study D6997C00002), FINDER 1 (Study D6997C00004), FINDER 2 (Study D6997C00006), and NEWEST (Study D6997C00003) studies], or from FALCON (Study D699BC00001) alone that compared Faslodex 500 mg with anastrozole 1 mg. Where frequencies differ between the pooled safety analysis and FALCON, the highest frequency is presented. The frequencies in Table 1 were based on all reported adverse drug reactions, regardless of the investigator assessment of causality. The median duration of fulvestrant 500 mg treatment across the pooled dataset (including the studies mentioned above plus FALCON) was 6.5 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-15T11:20:00Z · SHA-256 9f45335b79490cb1e57dbbfaec134717af9917dfaedd10e130c460e5e802a055 · Passage c595c139a975fcd0197124d3daa6cd298b830062a7f5ef3cf29c67b5a15d6d30 · Zeichen 371–1213 im Abschnitt